RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:3325

Classic heparin-induced thrombocytopenia

low confidenceDisorder

Also known as: Classic HAT · Classic HIT · Classic heparin-associated thrombocytopenia · HITT · Heparin-induced-immune thrombocytopenia

Publications

12,297

Trials

21

Interventional, condition-specific

Researchers

1,061

Distinct authors in sample

Gene link

—

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A rare drug-induced, immune-mediated prothrombotic disorder associated with thrombocytopenia and venous and/or arterial thrombosis.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (6)

HAT · HIT · heparin-associated thrombocytopenia · heparin-induced thrombocytopenia · heparin-induced thrombocytopenia (disease) · heparin-induced thrombocytopenia type 2

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    12,297 matched papers (7,046 in last 10 years) Source

  3. Phenotype characterisedPresent

    15 HPO annotations (e.g. Pulmonary embolism; Abnormal onset of bleeding; Thromboembolism) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPresent

    1 FDA designation (1 FDA orphan-indication approval) — e.g. bivalirudin Source

  6. Interventional trialPresent

    21 matched on ClinicalTrials.gov (1 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

15

Associated phenotypes · MONDO:0018048

  • Pulmonary embolism
  • Abnormal onset of bleeding
  • Thromboembolism
  • Deep venous thrombosis
  • Arterial thrombosis

Showing 5 of 15 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

1

Designation · 1 with FDA orphan-indication approval

  • FDA bivalirudinThrombocytopenia Heparin-induced thrombocytopenia Thrombosis · 2005-11-02 · Not FDA Approved for Orphan Indication

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

12,297

12,297 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

12,297 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

7,046 in the last 10 years · low confidence

Phrase hits: 12,297 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,061

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Warkentin TE11 papers · 2026

    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada; Transfusion Medicine, Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada; Service of Benign Hematology, Hamilton Health Sciences, Hamilton General Hospital, Hamilton, ON, Canada; McMaster Center for Transfusion Research, McMaster University, Hamilton, ON, Canada. Electronic address: twarken@mcmaster.ca.

    Papers in Europe PMC
  2. 02
    Nazy I9 papers · 2026

    Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada. Electronic address: nazyi@mcmaster.ca.

    Papers in Europe PMC
  3. 03
    Zhang Y7 papers · 2026

    Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.

    Papers in Europe PMC
  4. 04
    Arnold DM6 papers · 2026

    Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.

    Papers in Europe PMC
  5. 05
    Greinacher A6 papers · 2026

    Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, 17487, Greifswald, Deutschland.

    Papers in Europe PMC
  6. 06
    Hashemzadeh M6 papers · 2026

    University of Arizona College of Medicine, 6119 North Pinchot, Phoenix, AZ, 85750, USA. mhashemz1@yahoo.com.

    Papers in Europe PMC
  7. 07
    Bakchoul T5 papers · 2026

    Institute for Clinical and Experimental Transfusion Medicine, University Hospital of Tübingen, Tübingen, Germany; Centre for Clinical Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany. Electronic address: tamam.bakchoul@med.uni-tuebingen.de.

    Papers in Europe PMC
  8. 08
    Padmanabhan A5 papers · 2026

    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: padmanabhan.anand@mayo.edu.

    Papers in Europe PMC
  9. 09
    Wang D5 papers · 2026

    Versiti Blood Research Institute, Milwaukee, Wisconsin, United States.

    Papers in Europe PMC
  10. 10
    Althaus K4 papers · 2026

    Institute for Clinical and Experimental Transfusion Medicine, University Hospital of Tübingen, Tübingen, Germany; Centre for Clinical Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

21

interventional trials for this specific condition

21 interventional trials matched this specific condition name; 1 currently recruiting in our sample.

Data as of 11 September 2026

21 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 95th percentile).

low confidence · 95th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

21 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

22 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (1)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Classic heparin-induced thrombocytopenia — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Classic heparin-induced thrombocytopenia" OR "Classic HAT" OR "Classic HIT" OR "Classic heparin-associated thrombocytopenia" OR "Heparin-induced-immune thrombocytopenia" OR "heparin-associated thrombocytopenia" OR "heparin-induced thrombocytopenia" OR "heparin-induced thrombocytopenia (disease)" OR "heparin-induced thrombocytopenia type 2"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Classic heparin-induced thrombocytopenia" OR "Classic HAT" OR "Classic HIT" OR "Classic heparin-associated thrombocytopenia" OR "Heparin-induced-immune thrombocytopenia" OR "heparin-associated thrombocytopenia" OR "heparin-induced thrombocytopenia" OR "heparin-induced thrombocytopenia (disease)" OR "heparin-induced thrombocytopenia type 2"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 21 interventional · 22 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: HITT; HAT; HIT

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 3 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (12297) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T22:53:02.523Z